Clinical Research Papers:
Patients with high serum substance P levels previously to liver transplantation for hepatocellular carcinoma have higher risk of one-year liver transplantation mortality
Metrics: PDF 426 views | HTML 847 views | ?
Leonardo Lorente1, Sergio T. Rodriguez2, Pablo Sanz3, Antonia Pérez-Cejas4, Javier Padilla3, Dácil Díaz5, Antonio González5, María M. Martín2, Alejandro Jiménez6, Purificación Cerro7 and Manuel A. Barrera3
1Intensive Care Unit, Hospital Universitario de Canarias, Santa Cruz de Tenerife, 38320, Spain
2Intensive Care Unit, Hospital Universitario Nuestra Señora Candelaria, Santa Cruz de Tenerife, 38010, Spain
3Department of Surgery, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, 38010, Spain
4Laboratory Department, Hospital Universitario de Canarias, San Cristóbal de La Laguna, 38320, Spain
5Department of Digestive, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, 38010, Spain
6Research Unit, Hospital Universitario de Canarias, San Cristóbal de La Laguna, 38320, Spain
7Transplant Unit, Hospital Universitario Nuestra Señora Candelaria, Santa Cruz de Tenerife, 38010, Spain
Leonardo Lorente, email: firstname.lastname@example.org
Keywords: substance P; hepatocellular carcinoma; liver transplantation; mortality; outcome
Abbreviations: AFP: alpha-fetoprotein; AUC: area under curve; HCC: hepatocellular carcinoma; LT: liver transplantation; MELD: model for end-stage liver disease
Received: December 12, 2017 Accepted: March 23, 2018 Published: April 20, 2018
Purpose: Substance P is a tachykinins family member with inflammatory effects. Higher circulating levels of substance P have been found in patients with liver diseases and in patients with higher severity of liver diseases. The objective of this study was to determine whether serum levels of substance P levels, prior to liver transplantation (LT) for hepatocellular carcinoma (HCC) are associated with one-year LT mortality.
Material and Methods: In this observational retrospective unicenter study were included patients with LT for HCC. Serum levels of substance P were measured before LT. The end-point of the study was one-year mortality after LT.
Results: We found that one-year survivor patients (n = 127) showed a lower age in liver donors (p = 0.03) and lower levels of serum substance P levels (p = 0.003) than non-survivor patients (n = 15). Logistic regression analysis showed that serum levels of substance P (levels) were associated with one-year mortality (Odds Ratio = 1.011; 95% CI = 1.004–1.018; p = 0.002) controlling for the age of the LT donor.
Conclusions: We believe that our study is the first study reporting data on circulating levels of substance P previously to LT for HCC, and an association between elevated levels of serum substance P before LT and mortality during the first year of LT.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.